Multidisciplinary Respiratory Medicine最新文献

{"title":"Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysis.","authors":"Heinrich Matthys, Petra Funk, Andrea Zimmermann, Walter Lehmacher","doi":"10.4081/mrm.2023.914","DOIUrl":"10.4081/mrm.2023.914","url":null,"abstract":"<p><strong>Background: </strong>Acute bronchitis (AB) has an enormous economic impact through lost working time. We investigated whether treatment with <i>Pelargonium</i> extract EPs 7630 may reduce the time of inability to work.</p><p><strong>Methods: </strong>A meta-analysis of double-blind, randomized, placebo-controlled trials with adult patients suffering from AB was performed. The average number of days of inability to work and the proportion of patients who were still unable to work after one week's treatment were assessed.</p><p><strong>Results: </strong>Four clinical trials with a total of 1,011 evaluable patients who received the marketed dosage of EPs 7630 (n=505) or placebo (n=506) for seven days were included in the meta-analysis. At baseline, 845/1,011 patients (83.6%) were unable to work. In the four trials, the proportion decreased to between 19 and 14% for EPs 7630 and to between 41 and 55% for placebo (meta-analysis risk ratio and 95% confidence interval: 0.35; 0.26-0.45; p<0.001). For the number of sick days, a weighted mean difference of 1.73 days (1.17-2.29 days; p<0.001) favoring EPs 7630 was observed.</p><p><strong>Conclusions: </strong>For adults suffering from AB, this meta-analysis demonstrates that seven days' treatment with <i>Pelargonium sidoides</i> extract EPs 7630 significantly reduces the average number of sick days and significantly increases the proportion of patients who are able to return to work.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 1","pages":"914"},"PeriodicalIF":2.0,"publicationDate":"2023-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7e/f8/mrm-18-1-914.PMC10355130.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9848128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of interstitial lung disease in patients with autoimmune disease-related interstitial lung disease.","authors":"Kevin G Dsouza, Amanda S Alexander, Jubal R Watts, Tejaswini Kulkarni","doi":"10.4081/mrm.2023.890","DOIUrl":"10.4081/mrm.2023.890","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) is a common manifestation of systemic autoimmune diseases. A proportion of patients with autoimmune disease associated-ILDs develop progressive pulmonary fibrosis. Regular monitoring of patients with pulmonary fibrosis is recommended to enable prompt detection of progression and initiation or escalation of therapy if needed. However, there is no established algorithm for the treatment of autoimmune disease associated-ILDs. In this article, we present three case studies that demonstrate the challenges in the diagnosis and management of patients with autoimmune disease associated-ILDs and the importance of taking a multidisciplinary approach to their care.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 1","pages":"890"},"PeriodicalIF":2.0,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/e0/mrm-18-1-890.PMC10184176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9488795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The OM-85 bacterial lysate: a new tool against SARS-CoV-2?","authors":"Vadim Pivniouk, Donata Vercelli","doi":"10.4081/mrm.2023.906","DOIUrl":"10.4081/mrm.2023.906","url":null,"abstract":"<p><p>The emergence of SARS-CoV-2, a novel coronavirus, caused the global Coronavirus disease of 2019 (COVID-19) pandemic. Because SARS-CoV-2 mutates rapidly, vaccines that induce immune responses against viral components critical for target cell infection strongly mitigate but do not abrogate viral spread, and disease rates remain high worldwide. Complementary treatments are therefore needed to reduce the frequency and/or severity of SARS-CoV-2 infections. OM-85, a standardized lysate of 21 bacterial strains often found in the human airways, has immuno-modulatory properties and is widely used empirically in Europe, South America and Asia for the prophylaxis of recurrent upper airway infections in adults and children, with excellent safety profiles. <i>In vitro</i> studies from our laboratory recently demonstrated that OM-85 inhibits SARS-CoV-2 epithelial cell infection by downregulating SARS-CoV-2 receptor expression, raising the possibility that this bacterial extract might eventually complement the current COVID-19 therapeutic toolkit. Here we discuss how our results and those from other groups are fostering progress in this emerging field of research.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"906"},"PeriodicalIF":2.3,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/92/mrm-18-1-906.PMC9926922.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9209270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Germline variant of CTC1 gene in a patient with pulmonary fibrosis and myelodysplastic syndrome.","authors":"Martina Doubková,&nbsp;Zuzana Vrzalová,&nbsp;Marianna Štefániková,&nbsp;Libor Červinek,&nbsp;Kateřina Staňo Kozubík,&nbsp;Ivona Blaháková,&nbsp;Šárka Pospíšilová,&nbsp;Michael Doubek","doi":"10.4081/mrm.2023.909","DOIUrl":"https://doi.org/10.4081/mrm.2023.909","url":null,"abstract":"<p><strong>Introduction: </strong>Telomeropathies are associated with a wide range of diseases and less common combinations of various pulmonary and extrapulmonary disorders.</p><p><strong>Case presentation: </strong>In proband with high-risk myelodysplastic syndrome and interstitial pulmonary fibrosis, whole exome sequencing revealed a germline heterozygous variant of <i>CTC1</i> gene (c.1360delG). This \"frameshift\" variant results in a premature stop codon and is classified as likely pathogenic/pathogenic. So far, this gene variant has been described in a heterozygous state in adult patients with hematological diseases such as idiopathic aplastic anemia or paroxysmal nocturnal hemoglobinuria, but also in interstitial pulmonary fibrosis. Described <i>CTC1</i> gene variant affects telomere length and leads to telomeropathies.</p><p><strong>Conclusions: </strong>In our case report, we describe a rare case of coincidence of pulmonary fibrosis and hematological malignancy caused by a germline gene mutation in <i>CTC1</i>. Lung diseases and hematologic malignancies associated with short telomeres do not respond well to standard treatment.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 1","pages":"909"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/ae/mrm-18-1-909.PMC10316942.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9804945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Palliative care and end of life management in patients with idiopathic pulmonary fibrosis.","authors":"Assunta Micco,&nbsp;Emanuela Carpentieri,&nbsp;Antonio Di Sorbo,&nbsp;Alfredo Chetta,&nbsp;Mario Del Donno","doi":"10.4081/mrm.2023.896","DOIUrl":"https://doi.org/10.4081/mrm.2023.896","url":null,"abstract":"<p><p>Idiopathic pulmonary fibrosis (IPF) is a chronic disease with an unknown etiology that causes deterioration of the structure of the lung parenchyma, resulting in a severe and progressive decline in respiratory function and early mortality. IPF is essentially an incurable disease, with a mean overall survival of 5 years in approximately 20% of patients without treatment. The combination of a poor prognosis, uncertainty about the disease's progression, and the severity of symptoms has a significant impact on the quality of life of patients and their families. New antifibrotic drugs have been shown to slow disease progression, but their impact on health-related quality of life (HRQoL) has to be proven yet. To date, studies have shown that palliative care can improve symptom management, HRQoL, and end-of-life care (EoL) in patients with IPF, reducing critical events, hospitalization, and health costs. As a result, it is essential for proper health planning and patient management to establish palliative care early and in conjunction with other therapies, beginning with the initial diagnosis of the disease.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"896"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/57/f5/mrm-18-1-896.PMC9994447.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9108753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary study of assessing cognitive impairment in older patients with chronic obstructive pulmonary disease by using a cognitive functional assessment tool via a touchscreen personal computer.","authors":"Masahiro Ogawa,&nbsp;Ayame Uchiumi,&nbsp;Susumu Sato,&nbsp;Yoko Hamakawa,&nbsp;Mizuki Kobashi,&nbsp;Tomoki Aoyama,&nbsp;Hitoshi Tanimukai","doi":"10.4081/mrm.2023.892","DOIUrl":"https://doi.org/10.4081/mrm.2023.892","url":null,"abstract":"<p><strong>Background: </strong>Unique cognitive impairments related to chronic obstructive pulmonary diseases (COPD) have been increasingly reported. Considering the dementia risk and medication management, older patients with COPD should be evaluated for cognitive impairment. This study aimed to examine whether specific cognitive impairments related to COPD could be detected by an assessment tool using a touchscreen personal computer (PC) in older patients with COPD.</p><p><strong>Methods: </strong>This study included 28 older male patients with COPD and 30 healthy older male individuals. A touchscreen PC-based cognitive assessment application called CogEvo was used to assess and compare the cognitive function according to five domains: spatial cognition, orientation, working memory, executive function, and attention.</p><p><strong>Results: </strong>Analysis of variance showed an interaction effect on the indices of cognitive function based on five domains between the two groups, indicating differences in the characteristics of cognitive function in such groups. Betweengroup comparisons as a subtest showed that attention, executive function, and working memory were significantly lower in the COPD group than in the healthy group.</p><p><strong>Conclusions: </strong>CogEvo can detect specific cognitive impairments associated with COPD, suggesting that it can be potentially used as a screening tool for cognitive impairment in older patients with COPD.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"892"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/39/1a/mrm-18-1-892.PMC9926919.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10743317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute kidney injury in Coronavirus disease-19 related pneumonia in the intensive care unit: a retrospective multicenter study, Saudi Arabia.","authors":"Safwat A M Eldaboosy,&nbsp;Amgad Awad,&nbsp;Abdullah Farouk,&nbsp;Waheed Mahdy,&nbsp;Eman Abdelsalam,&nbsp;Sameh O Nour,&nbsp;Ahmed Kabil,&nbsp;Ahmad Taha,&nbsp;Sameh Makled,&nbsp;Ahmed Lotfi,&nbsp;Usama Nabway,&nbsp;Hatem Kanany","doi":"10.4081/mrm.2023.895","DOIUrl":"https://doi.org/10.4081/mrm.2023.895","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) poses a significant morbidity and mortality risk to critically ill COVID-19 patients. The aim of this study was to investigate the incidence, predictors, and outcomes of AKI in patients admitted to the intensive care unit (ICU) with critically ill COVID-19 pneumonia.</p><p><strong>Methods: </strong>A multicenter retrospective study in Saudi Arabia of adult patients aged at least 18 years diagnosed with COVID-19 pneumonia and admitted to the intensive care unit between May 2020 and May 2021 was conducted. The occurrence of AKI and associated risk factors, the need for continous renal replacement therapy (CRRT), and the outcome were reported.</p><p><strong>Results: </strong>The study included 340 patients admitted to the ICU with COVID-19. Their mean age was 66.7±13.4 years, ranging from 49 to 84 years, and most of them were men (63.8%). The most common concomitant diseases were hypertension (71.5%), diabetes (62.4%), IHD (37.6%), CKD (20%), heart failure (19.4%), and 81.2% suffered from ARDS. AKI occurred in 60.3% of patients, 38% were stage 1, 16.6% were stage 2, and 45.4% were stage 3. Approximately, 39% of patients required CRRT, out of which 76.2% were stage 3, which was significantly higher than the other stages (p<0.001). AKI patients suffered significantly from asthma and had lower levels of C-reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), and blood urea nitrogen (BUN) and higher creatinine levels than patients without AKI (p<0.05 all). The overall mortality rate was 39.4%, and the mortality rate was significantly higher in patients with AKI than in patients without AKI (48.3% <i>versus</i> 25.9%; p<0.001).</p><p><strong>Conclusion: </strong>AKI is common in adults admitted to the ICU with COVID-19 and is associated with an increased risk of death. Early detection of AKI and appropriate treatment can positively impact COVID-19 outcome. CRRT is the preferred dialysis method in critically ill ICU patients with AKI.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"895"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/dc/de/mrm-18-1-895.PMC10015944.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9145866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Underdiagnosis of silicosis revealed by reinterpretation of chest radiographs in Thai ceramic workers.","authors":"Supakorn Chansaengpetch,&nbsp;Narongpon Dumavibhat,&nbsp;Rathachai Kaewlai,&nbsp;Apinut Jaroonpipatkul,&nbsp;Tirathat Virojskulchai,&nbsp;Sitthiphon Bunman,&nbsp;Kawintra Khantharot,&nbsp;Arunee Pholngam,&nbsp;Thanabadee Thanakunchai","doi":"10.4081/mrm.2023.910","DOIUrl":"https://doi.org/10.4081/mrm.2023.910","url":null,"abstract":"<p><strong>Background: </strong>In Thailand, epidemiological data on silicosis in the ceramic sector is lacking and the underdiagnosis of silicosis remains an extensive concern. Therefore, this study aimed to determine the prevalence of silicosis and the extent of underdiagnosis among Thai ceramic workers by reinterpreting chest radiographs previously taken by a health check-up unit.</p><p><strong>Methods: </strong>This retrospective cross-sectional study was conducted on ceramic workers undergoing health surveillance using chest radiographs in one ceramic factory in September 2018. All chest radiographs were done retrospectively, then were reinterpreted by professional readers specially trained in using the ILO International Classification of Radiograph of Pneumoconioses (ILO/ICRP). Chest radiographs with a profusion of 1/1 or greater were suggestive of silicosis.</p><p><strong>Results: </strong>Out of the 244 participants undergoing chest radiography, the prevalence of silicosis was 2.9%. Overall, the mean age of the participants was 41 years, and 72.1% were female. Among individuals with silicosis, the median age was 43 years; 71.4% were male; the average employment duration was 26.9 years; while the male sex was the significant variable associated with silicosis with an odds ratio of 7.01 (95% confidence interval 1.31 to 37.4). Regarding the underdiagnosis, the health check-up unit failed to recognize all individuals with silicosis, and could not detect any radiographic chest abnormalities in 57.1% of those with silicosis.</p><p><strong>Conclusions: </strong>Despite the low prevalence of silicosis among Thai ceramic workers, this finding indicates ongoing exposure to silica in the ceramic industry. In addition, a significant proportion of the silicosis cases were underrecognized. Future efforts to prevent underdiagnosis and improve an occupational health surveillance service in Thailand are needed.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"910"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/46/9c/mrm-18-1-910.PMC10395368.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9941930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequent body position changes and physical activity as effective as standard care for infants hospitalised with acute respiratory infections - a randomised controlled trial.","authors":"Sonja Andersson Marforio,&nbsp;Christine Hansen,&nbsp;Eva Ekvall Hansson,&nbsp;Annika Lundkvist Josenby","doi":"10.4081/mrm.2023.885","DOIUrl":"https://doi.org/10.4081/mrm.2023.885","url":null,"abstract":"<p><strong>Background: </strong>No definite consensus has been reached yet on the best treatment strategy for the large group of infants hospitalised with bronchiolitis or pneumonia. Minimal handling is often recommended, although not evaluated scientifically. There is a need to evaluate the management, as the infants often are critically affected, and the costs for society are high. The aim of this RCT was to evaluate the most common physiotherapy intervention in Sweden for this patient group, including frequent changes in body position and stimulation of physical activity, compared to standard care.</p><p><strong>Methods: </strong>Infants 0-24 months old, without previous cardiac or respiratory diagnoses and born in gestational week 35+, were recruited in two Swedish hospitals. The participants (n=109) were randomised to either interventions in addition to standard care (intervention group) or to standard care alone (control group). The primary outcome measure was time to improvement. The secondary outcomes were immediate changes in oxygen saturation, heart rate and respiratory rate, time to improved general condition (parents' assessment), and lung complications.</p><p><strong>Results: </strong>The median time to improvement was 6 hours in both groups (p=0.54). The result was similar when we adjusted for age in months, sex, tobacco smoke exposure, heredity for asthma/atopic disease, and early stage of the infection (for those with RSV), p=0.69. Analyses of the immediate changes showed no significant differences either (p=0.49-0.89). Time to improved general condition was median 3 hours in the intervention group and 6 hours in the control group, p=0.76. No lung complications occurred.</p><p><strong>Conclusions: </strong>No statistically significant differences in outcomes were detected between the intervention group and the control group. Both strategies were found to be equally effective and safe, indicating that the current recommendation of minimal handling for these infants should be reconsidered. Furthermore, the findings suggest that this treatment can be safely continued.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 ","pages":"885"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ee/07/mrm-18-1-885.PMC9892929.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10663025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of viral co-infection on clinical outcomes and mortality of COVID-19 patients: a study from Saudi Arabia.","authors":"Usama E Abu Elhassan,&nbsp;Saad M A Alqahtani,&nbsp;Naif S Al Saglan,&nbsp;Ali Hawan,&nbsp;Khadejah M Alshahrani,&nbsp;Hana S Al-Malih,&nbsp;Mohammed A Alshehri,&nbsp;Faisal S Alqahtani,&nbsp;Fatimah Alshomrani,&nbsp;Roaa S Almtheeb,&nbsp;Ibrahim H E Feteih,&nbsp;Magda S R Abdelwahab,&nbsp;Ibrahim M A Mahmoud","doi":"10.4081/mrm.2023.915","DOIUrl":"https://doi.org/10.4081/mrm.2023.915","url":null,"abstract":"<p><strong>Background: </strong>In COVID-19 patients undetected co-infections may have severe clinical implications associated with prolonged hospitalization, ICU admission, and mortality. Therefore, we aimed to investigate the impact of viral coinfections on the outcomes of hospitalized patients with COVID-19 in a large tertiary Saudi Arabian Hospital.</p><p><strong>Methods: </strong>A total of 178 adult patients with confirmed SARS-CoV-2 who were hospitalized at the Armed Forces Hospital Southern Region (AFHSR), Saudi Arabia, from March 1^st to June 30^th 2022, were enrolled. Real-time PCR for the detection of viral co<i>‑</i>infections was carried out. Cases (SARS-CoV-2 with viral coinfections) and control (SARS-CoV-2 mono-infection) groups were compared.</p><p><strong>Results: </strong>12/178 (7%) of enrolled COVID-19 patients had viral coinfections. 82/178 (46%) of patients were males. 58% of patients had comorbidities. During the study period, 4/12 (33%) and 21/166 (13%) cases and control patients died, p=0.047, respectively. Duration of hospitalization was the only significant independent factor associated with SARS-CoV-2 coinfections, OR 1.140, 95% CI 1.020-1.274, p=0.021.</p><p><strong>Conclusions: </strong>The findings of this study from a large tertiary Saudi Arabian Center revealed a prevalence of 7% for SARS-CoV-2 viral coinfections. SARS-CoV-2 coinfected patients had a significantly prolonged duration of hospitalization and higher mortality than those with SARS-CoV-2 alone. Future studies are needed.</p>","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"18 1","pages":"915"},"PeriodicalIF":2.3,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/d1/mrm-18-1-915.PMC10230552.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9571931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}